Trial · NCT02539459
Adverse events37
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 37
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | oral mucositis | Infections and infestations | Treatment (Everolimus) | 14 | 20 | 20 |
| other | Alanine aminotransferase increase | Renal and urinary disorders | Treatment (Everolimus) | 10 | 20 | |
| other | anemia | Blood and lymphatic system disorders | Treatment (Everolimus) | 9 | 20 | |
| other | Aspartate aminotransferase increase | Renal and urinary disorders | Treatment (Everolimus) | 9 | 20 | |
| other | fatigue | General disorders | Treatment (Everolimus) | 7 | 20 | |
| other | Hypercholesterolemia | Blood and lymphatic system disorders | Treatment (Everolimus) | 7 | 20 | |
| other | Maculopapular rash | Skin and subcutaneous tissue disorders | Treatment (Everolimus) | 7 | 20 | |
| other | diarrhea | Gastrointestinal disorders | Treatment (Everolimus) | 5 | 20 | |
| other | Leukocyte decrease | Blood and lymphatic system disorders | Treatment (Everolimus) | 5 | 20 | |
| other | Hypertriglyceridemia | Blood and lymphatic system disorders | Treatment (Everolimus) | 4 | 20 | |
| other | Pruritis | Skin and subcutaneous tissue disorders | Treatment (Everolimus) | 4 | 20 | |
| other | constipation | Gastrointestinal disorders | Treatment (Everolimus) | 3 | 20 | |
| other | Xerostomia | General disorders | Treatment (Everolimus) | 3 | 20 | |
| other | Lymphocyte decrease | Blood and lymphatic system disorders | Treatment (Everolimus) | 3 | 20 | |
| other | Hyperglycemia | Metabolism and nutrition disorders | Treatment (Everolimus) | 3 | 20 | |
| other | Metabolism + nutrional disorders - other | Metabolism and nutrition disorders | Treatment (Everolimus) | 3 | 20 | |
| other | Dysgeusia | General disorders | Treatment (Everolimus) | 3 | 20 | |
| other | cough | Respiratory, thoracic and mediastinal disorders | Treatment (Everolimus) | 3 | 20 | |
| other | Epistaxis | Vascular disorders | Treatment (Everolimus) | 3 | 20 | |
| other | Skin + subcutaneous tissue disorders - other | Skin and subcutaneous tissue disorders | Treatment (Everolimus) | 3 | 20 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02539459/events